Aurora Cannabis appointed Faris El Refaie as Executive Vice President, Global Commercial, effective September 28, 2026. This newly created role tasks El Refaie with overseeing the global commercial function to accelerate market strategy and customer engagement across Canada, Europe, Australia, New Zealand, and other international markets. El Refaie brings 25 years of biopharmaceutical experience from JAMP Pharma Group, GSK, and AstraZeneca. Aurora Cannabis Inc. operates in the medical cannabis industry.

Aurora Cannabis Inc. filed a Directors' Circular unanimously recommending shareholders reject a hostile takeover bid from Curaleaf Holdings, urging them to take no action and not tender their shares. The Board argues the offer undervalues Aurora, which is debt-free with approximately $149 million in cash, while exposing shareholders to Curaleaf's over $1 billion in debt and governance risks. Aurora's leadership asserts that accepting the bid would weaken shareholder voting rights, reducing ownership influence to approximately 3.2% of votes despite holding roughly 7.7% of equity in a combined entity. Independent analysts support the view that the bid fails to reflect Aurora's fundamental value or growth potential. Aurora Cannabis Inc. operates as a global leader in medical cannabis, manufacturing and distributing products across Canada, Europe, Australia, and New Zealand.

Aurora Cannabis filed a 6-K to release a news refuting inaccurate statements made by Curaleaf Holdings in support of its unsolicited hostile takeover bid. Aurora's Board, assisted by a Special Committee, is reviewing the proposal and advised shareholders to take no action pending a formal recommendation. The company highlighted that international net revenue grew 17% year-over-year in fiscal Q1'27, driven by strong performance in Germany where reimbursement changes impacted less than 10 percent of volume. Aurora also noted record global medical cannabis revenue and adjusted EBITDA for FY2026, alongside an August 19 acquisition of Internode Pharma Limited and HAP Pharma Limited to expand UK distribution. The company operates in the global medical cannabis industry.

Aurora Cannabis acquired Internode Pharma Limited and HAP Pharma Limited for GBP 2.1 million in cash to expand its distribution access in the UK medical cannabis market. The transaction provides Aurora with direct ownership of a licensed import facility and virtual pharmacy, aiming to streamline supply chains and increase market share. This strategic move supports the company's goal of leveraging operational expertise to serve growing patient demand in the UK. Aurora Cannabis Inc. operates in the global medical cannabis industry.